VVM
BOLD

Versant Venture Management’s Audentes Therapeutics, Inc BOLD Stock Holding History

Versant Venture Management’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-553,916
Closed -$15.6M – 8
2019
Q3 		$15.6M Hold
553,916
– – 6.02% 4
2019
Q2 		$21M Sell
553,916
-249,190
-31% -$9.57M 6.11% 4
2019
Q1 		$31.3M Sell
803,106
-401,509
-33% -$11.5M 10.32% 3
2018
Q4 		$25.7M Hold
1,204,615
– – 12.71% 3
2018
Q3 		$47.7M Hold
1,204,615
– – 16.22% 2
2018
Q2 		$46M Hold
1,204,615
– – 14.36% 2
2018
Q1 		$36.2M Hold
1,204,615
– – 11.58% 2
2017
Q4 		$37.6M Sell
1,204,615
-602,217
-33% -$16.5M 39.61% 1
2017
Q3 		$50.9M Hold
1,806,832
– – 38.71% 1
2017
Q2 		$34.6M Hold
1,806,832
– – 27.2% 1
2017
Q1 		$30.8M Hold
1,806,832
– – 22.39% 2
2016
Q4 		$33M Hold
1,806,832
– – 32.13% 1
2016
Q3 		$32.2M Buy
+1,806,832
New +$27.4M 35.88% 1

Other funds holding BOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Versant Venture Management's BOLD Position: Q4 2019 in Review

Versant Venture Management sold out of Audentes Therapeutics, Inc (BOLD) in Q4 2019, closing a stake of 553,916 shares — an estimated $15.6M sold.

Versant Venture Management first reported a position in BOLD in Q3 2016 and held it in 13 quarters. The position peaked at $50.9M in Q3 2017. 188 funds tracked by Wall St. Rank hold BOLD as of Q4 2019.

  • Versant Venture Management reported no remaining Audentes Therapeutics, Inc position as of Q4 2019 after selling out during the quarter.
  • Versant Venture Management sold 553,916 Audentes Therapeutics, Inc shares in Q4 2019, an estimated $15.6M.
  • Versant Venture Management first reported a position in Audentes Therapeutics, Inc in Q3 2016 and held it in 13 quarters.
  • Versant Venture Management's Audentes Therapeutics, Inc position peaked at $50.9M in Q3 2017.
  • 188 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q4 2019.

Based on Versant Venture Management's 13F filing for Q4 2019, filed 21 Jan 2020.